The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 63.50
Bid: 62.00
Ask: 65.00
Change: 1.00 (1.60%)
Spread: 3.00 (4.839%)
Open: 62.50
High: 63.50
Low: 62.50
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM & Board Changes

29 Jun 2023 11:04

RNS Number : 3975E
NetScientific PLC
29 June 2023
 

For immediate release

NetScientific plc

("NetScientific", "Group" or the "Company")

Result of Annual General Meeting and Board Changes

NetScientific plc (AIM: NSCI), the deep tech and life sciences VC investment group, announces that all resolutions set out in the 2023 Notice of Annual General Meeting sent to shareholders were duly passed at the Company's Annual General Meeting held earlier today.

Result of Annual General Meeting

Resolutions 1 to 9 were passed as Ordinary Resolutions and Resolution 10 was passed as a Special Resolution. The proxy voting results are as follows:

 

Resolution

For

%

Against

%

Vote Total

Vote Total as % of Issued Share Capital

Withheld*

1. To receive and adopt the Company's Annual Report and Accounts for the period ended 31 December 2022

6,910,987

100%

686

0%

6,911,673

29%

-

2. To receive and approve the Directors' Remuneration Report

6,871,686

99%

39,975

1%

6,911,661

29%

12

3. To reappoint BDO LLP as auditors for the forthcoming year

6,873,987

99%

37,686

1%

6,911,673

29%

-

4. To authorise Audit Committee in determining Auditors' remuneration

6,910,987

100%

686

0%

6,911,673

29%

-

5. To confirm the reappointment of Dr Ilian Iliev as a director

6,905,598

100%

6,075

0%

6,911,673

29%

-

6. To confirm the reappointment of Edward Hooper as a director

6,905,598

100%

6,075

0%

6,911,673

29%

-

7. To confirm the reappointment of Dr Jonathan Robinson as a director

6,905,598

100%

6,075

0%

6,911,673

29%

-

8. To confirm the reappointment of Dr Charles Spicer as a director

6,897,104

100%

6,075

0%

6,903,179

29%

8,494

9. To authorise the Directors to allot relevant securities pursuant to section 551 of the Companies Act 2006

6,865,004

99%

46,669

1%

6,911,673

29%

-

10. To disapply pre-emption rights on the allotment of securities or sale of treasury shares in connection with a pre-emptive offer or on allotment of shares

6,810,004

99%

101,669

1%

6,911,673

29%

-

 

* A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

Board Changes

Further to the announcement made on 3 April 2023, Prof Stephen Smith has retired from the NetScientific Board with effect from the closing of the AGM. It is anticipated that he will remain an adviser to a number of the Group's life sciences portfolio companies.

Further to the announcement made on 31 May 2023, Dr Charles Spicer has taken over as Chair with effect from the closing of the AGM. Dr Jonathan Robinson has retired as Interim Chair and moves to the role of Senior Independent Director.

Dr Ilian Iliev, Chief Executive Officer of the Company, commented:

"On behalf of the Company and the Board, I extend a warm welcome to Charles as he joins our team. We are looking forward to working with him and benefiting from his expertise. Additionally, I would like to express my appreciation to Prof. Stephen Smith for his dedicated service since 2016. We greatly value his ongoing counsel and understanding of the life sciences sector. Finally, I would like to extend my gratitude to Jonathan Robinson for his interim board leadership. We look forward to continuing to work alongside him in his new role as Senior Independent Director."

Dr Charles Spicer, Chair of the Company, commented:

"I am excited by the future prospects of the Company and eagerly anticipate working with Ilian and the wider team. Our primary objective will be to drive shareholder returns through profitable exits and strategic expansion of our portfolio."

 

For more information, please contact:

 

NetScientific

Ilian Iliev, CEO Via Belvedere Communications

 

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel / Enzo Aliaj +44 (0)20 7220 1666

 

Belvedere Communications

John West / Llew Angus +44 (0) 203 008 6867

Email: nsci@belvederepr.com

 

About NetScientific

NetScientific plc (AIM: NSCI) is deep tech and life sciences VC investment group with an international portfolio of innovative companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-light investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGGCGDLCUDDGXC
Date   Source Headline
17th Dec 20193:04 pmRNSHolding(s) in Company
13th Dec 20191:21 pmRNSBoard Changes
21st Nov 20197:00 amRNSGlycotest receives 2nd $3m tranche of $10m finance
17th Oct 20192:14 pmRNSHolding(s) in Company
14th Oct 20197:00 amRNSAppointment to the Board
3rd Oct 20191:44 pmRNSPDS collaborates with Merck in Phase 2 studies
1st Oct 20192:10 pmRNSPDS prioritise PDS0101 in high risk HPV to Phase 2
19th Sep 20191:24 pmRNSPDS - positive data for immunotherapy treatment
19th Sep 201911:00 amRNSInterim Results for six months ended 30 June 2019
1st Aug 20191:44 pmRNSPDS second quarter 2019 financial results
31st Jul 20198:41 amRNSPDS Biotechnology Corp liquidity funding program
9th Jul 20192:58 pmRNSHolding(s) in Company
8th Jul 20194:04 pmRNSHolding(s) in Company
18th Jun 20192:27 pmRNSResult of Annual General Meeting
31st May 20197:00 amRNSPositive new data demonstrates NEATstiks potential
24th May 20199:50 amRNSNotice of AGM and Annual Report & Accounts
22nd May 20197:00 amRNSFull Year Results for the year ended 31 Dec 2018
16th May 20193:07 pmRNSPDS Biotechnology journal publication
25th Apr 20197:00 amRNSResignation of CEO
22nd Mar 20194:42 pmRNSSale of Wanda and Vortex
19th Mar 20197:00 amRNSPDS merger with Edge Therapeutics update
18th Mar 20192:09 pmRNSPDS completes merger with Edge Therapeutics
18th Mar 20192:07 pmRNSOrderly wind up of Wanda and Vortex
14th Mar 20197:00 amRNSShare Price Movement
4th Mar 201911:45 amRNSResults of General Meeting
1st Mar 201911:15 amRNSUpdate on upcoming General Meeting
27th Feb 20194:40 pmRNSSecond Price Monitoring Extn
27th Feb 20194:35 pmRNSPrice Monitoring Extension
27th Feb 20192:05 pmRNSSecond Price Monitoring Extn
27th Feb 20192:00 pmRNSPrice Monitoring Extension
25th Feb 201912:54 pmRNSHolding(s) in Company
21st Feb 20194:35 pmRNSHolding(s) in Company
20th Feb 201910:51 amRNSHolding(s) in Company
19th Feb 20192:06 pmRNSSecond Price Monitoring Extn
19th Feb 20192:00 pmRNSPrice Monitoring Extension
18th Feb 20194:54 pmRNSHolding(s) in Company
18th Feb 201911:06 amRNSSecond Price Monitoring Extn
18th Feb 201911:00 amRNSPrice Monitoring Extension
15th Feb 201912:00 pmRNSConclusion of Strategic Review
14th Feb 201912:07 pmRNSGlycotest Receives First $3m Tranche from Fosun
15th Jan 201911:08 amRNSTermination of Formal Sales Process
15th Jan 20199:37 amRNSForm 8.5 - NetScientific plc
14th Jan 201910:25 amRNSForm 8.5 - NetScientific PLC
8th Jan 201911:58 amRNSForm 8.5 - NetScientific PLC
7th Jan 201910:14 amRNSForm 8.5 - NetScientific PLC
4th Jan 20199:13 amRNSForm 8.5 - NetScientific PLC
31st Dec 20189:36 amRNSForm 8.5 - NetScientific PLC
24th Dec 201810:23 amRNSForm 8.5 - NetScientific PLC
21st Dec 201811:04 amRNSForm 8.5 - NetScientific PLC
20th Dec 20184:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.